Introduction {#section1-1534735418794885}
============

Chemotherapy- and radiotherapy-induced mucositis is a significant burden for cancer patients ([Table 1](#table1-1534735418794885){ref-type="table"}). Symptoms of oral mucositis become apparent 5 to 10 days after chemotherapy and may progress from erythema, cracking, and inflammation to pain, bleeding, ulceration,^[@bibr1-1534735418794885],[@bibr2-1534735418794885]^ and pain.^[@bibr1-1534735418794885],[@bibr3-1534735418794885]^ Pelvic radiotherapy is reported to induce changes in the bowel habits of 90% of patients, with half of all patients reporting that quality of life is significantly adversely affected,^[@bibr4-1534735418794885]^ and that serious complications can persist decades post treatment cessation.^[@bibr4-1534735418794885][@bibr5-1534735418794885]-[@bibr6-1534735418794885]^ Epidemiological studies on cancers of the head and neck report a prevalence of oral mucositis of 80% for patients undergoing radiotherapy and 40% of patients receiving chemotherapy.^[@bibr3-1534735418794885]^ Moreover with high-dose chemotherapy, mucositis can develop in 100% of bone marrow transplant patients. Mucositis is the most frequent and serious reported side effect in the first 3 months following a transplant and is the most common condition requiring systemic analgesics during cancer therapy.^[@bibr3-1534735418794885]^ The frequency of mucositis is also higher in patients receiving continuous infusion therapy for breast and colon cancer.^[@bibr7-1534735418794885]^

###### 

Chemoradiotherapy-Induced Gastrointestinal Toxicities.

![](10.1177_1534735418794885-table1)

  Intervention                                                                                                                                                                                           Pathophysiology                                                                                                                                  Possible Symptoms
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------
  Radiotherapy^[@bibr138-1534735418794885][@bibr139-1534735418794885][@bibr140-1534735418794885]-[@bibr141-1534735418794885]^                                                                            Direct epithelial injury                                                                                                                         Mouth ulcers
  Mucositis                                                                                                                                                                                              Pain                                                                                                                                             
  Loss of mitotic activity                                                                                                                                                                               Anorexia                                                                                                                                         
  Acute inflammation                                                                                                                                                                                     Bloating dysphagia                                                                                                                               
  Abscess formation                                                                                                                                                                                      Diarrhea                                                                                                                                         
  Swelling of vascular endothelial lining                                                                                                                                                                Lactose intolerance malabsorption                                                                                                                
  Tissue ischemia mucosal friability                                                                                                                                                                     Nausea                                                                                                                                           
  Neovascularization progressive fibrosis                                                                                                                                                                Ulceration                                                                                                                                       
                                                                                                                                                                                                         Weight loss                                                                                                                                      
                                                                                                                                                                                                         IBS                                                                                                                                              
                                                                                                                                                                                                         ISBO                                                                                                                                             
  Irinotecan^[@bibr6-1534735418794885],[@bibr142-1534735418794885][@bibr143-1534735418794885]-[@bibr144-1534735418794885]^                                                                               Cholinergically mediated diarrhea                                                                                                                Rhinitis
  Cytokine release                                                                                                                                                                                       Early-onset diarrhea                                                                                                                             
  Altered motility                                                                                                                                                                                       Abdominal cramping                                                                                                                               
  Villous blunting and crypt degeneration                                                                                                                                                                Malabsorption                                                                                                                                    
  TJ dysfunction                                                                                                                                                                                         Delayed-onset diarrhea                                                                                                                           
  Changes to claudin-1 and occludin                                                                                                                                                                                                                                                                                                                       
  Bacterial translocation                                                                                                                                                                                                                                                                                                                                 
  Fluoropyrimidines including 5-FU^[@bibr8-1534735418794885],[@bibr145-1534735418794885][@bibr146-1534735418794885][@bibr147-1534735418794885][@bibr148-1534735418794885]-[@bibr149-1534735418794885]^   Gastrointestinal mucositis                                                                                                                       Altered bowel movement
  Villi shortening, increased crypt depth                                                                                                                                                                Diarrhea                                                                                                                                         
  Increased intestinal myeloperoxidase activity, reduced glutathione (GSH) concentrations, and increased levels of inflammatory mediators                                                                Lactose intolerance                                                                                                                              
  Reduced expressions of occludin and claudin-1 and TJ dysfunction                                                                                                                                       Malabsorption                                                                                                                                    
                                                                                                                                                                                                         SIBO                                                                                                                                             
  Paclitaxel^[@bibr150-1534735418794885],[@bibr151-1534735418794885]^                                                                                                                                    Increase apoptosis of intestinal villi, increased intestinal permeability, reduced white blood cell count, and induced bacterial translocation   Stomatitis
                                                                                                                                                                                                         Vomiting                                                                                                                                         
                                                                                                                                                                                                         Diarrhea                                                                                                                                         
                                                                                                                                                                                                         Colitis                                                                                                                                          
  Oxaliplatin^[@bibr151-1534735418794885],[@bibr152-1534735418794885]^                                                                                                                                   DNA denaturation and neuronal ablation                                                                                                           Potentiation of 5-FU related GIT toxicities
  Apoptosis of intestinal epithelial cells                                                                                                                                                               Anorexia                                                                                                                                         
  Inflammation                                                                                                                                                                                           Stomatitis                                                                                                                                       
  Bacterial translocation                                                                                                                                                                                Nausea                                                                                                                                           
  Sepsis                                                                                                                                                                                                 Emesis                                                                                                                                           
                                                                                                                                                                                                         Diarrhea/constipation                                                                                                                            
  Lapatinib^[@bibr153-1534735418794885]^                                                                                                                                                                 Increased jejunal crypt length, increased mitotic rate, and goblet cell morphology                                                               Malabsorption
                                                                                                                                                                                                         Altered bowel function                                                                                                                           
                                                                                                                                                                                                         Diarrhea                                                                                                                                         
  Methotrexate^[@bibr154-1534735418794885]^                                                                                                                                                              Reduced claudin-1 and occludin expression and TJ dysfunction                                                                                     Inflammation
  Increased proinflammatory cytokine production                                                                                                                                                          Sepsis                                                                                                                                           
                                                                                                                                                                                                         Neutropenia                                                                                                                                      
  Taxanes^[@bibr151-1534735418794885]^                                                                                                                                                                   Ischemic colitis                                                                                                                                 Nausea
  Neutropenia                                                                                                                                                                                            Diarrhea                                                                                                                                         
  Mucosal edema                                                                                                                                                                                          Emesis                                                                                                                                           
  Hemorrhage                                                                                                                                                                                             Stomatitis                                                                                                                                       
  Inflammatory infiltrates                                                                                                                                                                               Colitis                                                                                                                                          
  Ulceration                                                                                                                                                                                             Hepatitis                                                                                                                                        
  Cisplatin, carboplatin^[@bibr151-1534735418794885],[@bibr155-1534735418794885]^                                                                                                                        Decreased total surface area of villi                                                                                                            Anorexia
  Reduced villus height and villus/crypt ratio                                                                                                                                                           Stomatitis                                                                                                                                       
  Decreased intestinal motility                                                                                                                                                                          Nausea                                                                                                                                           
  Altered digestive and metabolic functions                                                                                                                                                              Emesis                                                                                                                                           
  Inflammatory infiltrates                                                                                                                                                                               Diarrhea                                                                                                                                         
                                                                                                                                                                                                         Malabsorption                                                                                                                                    
  Anthracyclines^[@bibr151-1534735418794885]^                                                                                                                                                            Inflammation                                                                                                                                     Stomatitis
  Steatosis                                                                                                                                                                                              Ulceration                                                                                                                                       
                                                                                                                                                                                                         Anorexia                                                                                                                                         
                                                                                                                                                                                                         Diarrhea                                                                                                                                         
                                                                                                                                                                                                         Nausea                                                                                                                                           
                                                                                                                                                                                                         Emesis                                                                                                                                           
  Cytarabine, gemcitabine^[@bibr151-1534735418794885]^                                                                                                                                                   Necrotizing colitis                                                                                                                              Anorexia
  Veno-occlusive disease                                                                                                                                                                                 Nausea                                                                                                                                           
                                                                                                                                                                                                         Emesis                                                                                                                                           
                                                                                                                                                                                                         Ulceration                                                                                                                                       
                                                                                                                                                                                                         Diarrhea                                                                                                                                         

Abbreviations: IBS, irritable bowel syndrome; ISBO, intermittent small bowel obstruction; TJ, tight junctions; 5-FU, 5-fluorouracil; SIBO, small intestinal overgrowth syndrome.

Unlike oral mucositis, clinical data reflecting the long-term effects of treatment-induced gastrointestinal mucositis are lacking. An important and debilitating symptom of intestinal mucositis is diarrhea. Gastrointestinal mucositis has been reported in 80% of patients treated with 5-fluorouracil (5-FU).^[@bibr8-1534735418794885]^ The frequency of chemotherapy-induced diarrhea depends on the drug administered and the schedule implemented. The highest rate of diarrhea has been reported to occur with a weekly regimen of irinotecan and 5-FU bolus with 10% of patients going on to develop grade 3 to 4 mucositis. Late-onset diarrhea may occur within a week following higher dosages of irinotecan and after approximately 2 weeks following a weekly administration of lower doses.^[@bibr9-1534735418794885]^ In stage III colorectal cancer (CRC), chemotherapy with FOLFOX induced diarrhea in 56% of patients, yet with FOLFIRI, the prevalence of diarrhea increased to 89%. The risk of a first episode was highest during the first cycle (35 %) and dropped to less than 10% during subsequent cycles.^[@bibr10-1534735418794885]^

The frequency of treatment-induced gastrointestinal toxicity in CRC has been posited to likely increase with the introduction of novel drugs and the use of more intense combination regimens of polychemotherapy combined with monoclonal antibodies.^[@bibr6-1534735418794885],[@bibr10-1534735418794885]^ Targeted therapies, including erlotinib, gefitinib, lapatinib, sorafenib, and sunitinib, have been associated with a 2- to 8-fold increased risk of all or high-grade diarrhea compared with conventional chemotherapy regimens.^[@bibr11-1534735418794885]^

Despite several interventions being available, including cryotherapy and loperamide, for the control of oral mucositis and diarrhea, respectively, there is a need to further explore additional safe and effective preventative and treatment options for treatment-induced mucositis and related symptoms. The goal of this narrative review was to present an overview of the safety and efficacy reported for various interventions posited to reduce the adverse effects of antineoplastic agents. The majority of clinical research has focused on prevention or treatment of oral mucositis, while intestinal toxicity has been less well reported.

Methods {#section2-1534735418794885}
=======

The inclusion criteria were any type of clinical trial examining the use of any oral or topical probiotic or nutritional intervention with both the abstract and the journal article written in English. All clinical trial designs and methodology were included, namely, prevention as well as treatment studies. The following databases were used to retrieve journal articles: PubMed, the Cochrane Library, Science Direct, Scopus, Embase, and Google Scholar, and searches were current up to November 2016.

Electronic databases were searched using the following search string:

1.  Probiotics OR Diet OR Food OR Nutrition OR Micronutrients OR Vitamins OR Minerals OR Dietary supplements OR Functional foods OR Honey AND Chemotherapy AND Mucositis AND Chemotherapy AND Diarrhea AND Radiotherapy AND Mucositis AND Radiotherapy AND Diarrhea.

Examination of references in retrieved articles was also conducted.

Results {#section3-1534735418794885}
=======

Fifty articles examining various nutritional compounds were identified, 49 from PubMed and 1 from Embase.^[@bibr12-1534735418794885]^ Reports included 1 study on activated charcoal,^[@bibr13-1534735418794885]^ 1 study on β-glucan,^[@bibr14-1534735418794885]^ 2 studies on multinutrient formulations,^[@bibr15-1534735418794885],[@bibr16-1534735418794885]^ 2 studies on an amino acid--rich oral formulation,^[@bibr17-1534735418794885],[@bibr18-1534735418794885]^ 1 study with folic acid with B~12~,^[@bibr19-1534735418794885]^ 5 studies on vitamin E,^[@bibr12-1534735418794885],[@bibr20-1534735418794885][@bibr21-1534735418794885][@bibr22-1534735418794885]-[@bibr23-1534735418794885]^ 17 intervention studies containing minerals,^[@bibr24-1534735418794885][@bibr25-1534735418794885][@bibr26-1534735418794885][@bibr27-1534735418794885][@bibr28-1534735418794885][@bibr29-1534735418794885][@bibr30-1534735418794885][@bibr31-1534735418794885][@bibr32-1534735418794885][@bibr33-1534735418794885][@bibr34-1534735418794885][@bibr35-1534735418794885][@bibr36-1534735418794885][@bibr37-1534735418794885][@bibr38-1534735418794885][@bibr39-1534735418794885]-[@bibr40-1534735418794885]^ and 21 studies with glutamine ([Table 2](#table2-1534735418794885){ref-type="table"}).^[@bibr41-1534735418794885][@bibr42-1534735418794885][@bibr43-1534735418794885][@bibr44-1534735418794885][@bibr45-1534735418794885][@bibr46-1534735418794885][@bibr47-1534735418794885][@bibr48-1534735418794885][@bibr49-1534735418794885][@bibr50-1534735418794885][@bibr51-1534735418794885][@bibr52-1534735418794885][@bibr53-1534735418794885][@bibr54-1534735418794885][@bibr55-1534735418794885][@bibr56-1534735418794885][@bibr57-1534735418794885][@bibr58-1534735418794885][@bibr59-1534735418794885][@bibr60-1534735418794885]-[@bibr61-1534735418794885]^ Moreover, 25 clinical trials were identified examining honey alone or in combination as a prophylaxis/intervention for oral mucositis ([Table 3](#table3-1534735418794885){ref-type="table"}).^[@bibr62-1534735418794885][@bibr63-1534735418794885][@bibr64-1534735418794885][@bibr65-1534735418794885][@bibr66-1534735418794885][@bibr67-1534735418794885][@bibr68-1534735418794885][@bibr69-1534735418794885][@bibr70-1534735418794885][@bibr71-1534735418794885][@bibr72-1534735418794885][@bibr73-1534735418794885][@bibr74-1534735418794885][@bibr75-1534735418794885][@bibr76-1534735418794885][@bibr77-1534735418794885][@bibr78-1534735418794885][@bibr79-1534735418794885][@bibr80-1534735418794885][@bibr81-1534735418794885][@bibr82-1534735418794885][@bibr83-1534735418794885][@bibr84-1534735418794885][@bibr85-1534735418794885][@bibr86-1534735418794885]-[@bibr87-1534735418794885]^

###### 

Clinical Trials Investigating Nutrients for Oral and Intestinal Mucositis.

![](10.1177_1534735418794885-table2)

  References                                               Treatment                                       Intervention                                                                                                                                                                                     Cancer Type                       Design (n = Subjects), Assessment                               Outcome
  -------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------- --------------------------------------------------------------- -----------------------------------------------------------------------------
  *Oral mucositis*                                                                                                                                                                                                                                                                                                                                                                                            
  Karac et al^[@bibr14-1534735418794885]^                  Chemotherapy (FOLFOX-4)                         Beta-glucan 50 mg/day versus no treatment                                                                                                                                                        CRC                               Retrospective, controlled (n = 62), CTCAE                       Decreased incidence OM and diarrhea
  Casbarien et al^[@bibr15-1534735418794885]^              Chemotherapy and radiotherapy                   Multinutrient formulation (Supportan)                                                                                                                                                            HNC                               Open-label study (n = 7), CTCAE                                 OM none severe
  Machon et al^[@bibr16-1534735418794885]^                 Chemotherapy and radiotherapy                   Multinutrient formulation (Oral Impact)                                                                                                                                                          HNC                               Prospective noncontrolled (n = 31), CTCAE                       Decreased OM severity
  Harada et al^[@bibr17-1534735418794885]^                 Radiotherapy ± chemotherapy                     Amino acid--rich oral formulation (Elental) versus no treatment                                                                                                                                  OC                                Retrospective study (n = 74), CTCAE                             Decreased OM severity and increased Tx completion rates
  Ogata et al^[@bibr18-1534735418794885]^                  5-FU-based chemotherapy                         Amino acid--rich oral formulation (Elental)                                                                                                                                                      CRC                               Prospective pilot study (n = 22), CTCAE                         Decreased OM severity (*P* = .0002)
  Azzoli et al^[@bibr19-1534735418794885]^                 Pralatrexate                                    Folic acid IM/B~12~ oral                                                                                                                                                                         NSCLC                             Nonrandomized, multicenter (n = 39), CTCAE                      NS decrease OM
  Ghoreishi et al^[@bibr12-1534735418794885]^              Cyclophosphamide-based conditioning regimen     Vitamin E 400 mg versus placebo                                                                                                                                                                  ALL/AML/CML                       RCT (n = 39), CTCAE                                             NS decrease OM
  Ferreira et al^[@bibr20-1534735418794885]^               Radiotherapy                                    Topical vitamin E, 400 mg versus placebo                                                                                                                                                         HNC                               RCT (n = 54), RTOG                                              Decreased OM risk of 36%
  Wadleigh et al^[@bibr21-1534735418794885]^               5-FU infusion/cisplatin or doxorubicin          Topical vitamin E, 400 mg versus placebo                                                                                                                                                         HNC/OeC; HCC/AML                  RCT (n = 18), WHO OMAS                                          Decreased OM (*P* \< .05; vitamin E 60% complete resolution)
  El-Housseiny et al^[@bibr22-1534735418794885]^           Chemotherapy                                    Topical vitamin E 100 mg versus 40 mg/kg/daily IM                                                                                                                                                OC                                Comparative randomized study (pediatric, n = 80), WHO OMAS      Decreased OM severity (*P* \< .05)
  Khurana et al^[@bibr23-1534735418794885]^                Chemotherapy                                    Topically vitamin E compared with pycnogenol, glycerin, water                                                                                                                                    AL/NHL                            Single-blind, randomized (n = 72, pediatric), WHO OMAS          Decreased OM severity (*P* \< .05) with vitamin E
  Büntzel et al^[@bibr24-1534735418794885]^                Chemotherapy and radiotherapy                   Sodium selenite oral fluid 0.5 mg versus no treatment                                                                                                                                            HNC                               RCT (n = 39), RTOG                                              NS benefit
  Jahangard-Rafsanjani et al^[@bibr25-1534735418794885]^   HDC HSCT conditioning regimen                   Selenium 200 µg versus placebo                                                                                                                                                                   ALL/AML                           RCT (n = 64), WHO OMAS                                          Decreased OM severity grade 3-4 (*P* \< .05)
  Watanabe et al^[@bibr26-1534735418794885]^               Chemotherapy and radiotherapy                   Zinc L-carnosine solution versus azulene rinse                                                                                                                                                   HNC                               RCT (n = 31), CTCAE                                             Decreased OM severity ⩾grade 2 (*P* \< .05)
  Lin et al^[@bibr27-1534735418794885]^                    Chemotherapy and radiotherapy                   Zinc chelate equiv 25 mg 2-4 times daily versus placebo                                                                                                                                          HNC                               RCT (n = 100), RTOG                                             Decreased OM severity grade 3 radiotherapy only
  Lin et al^[@bibr28-1534735418794885]^                    Radiotherapy                                    Zinc chelate equiv 25 mg 2-4 times daily versus placebo                                                                                                                                          NPC/OC                            RCT (n = 100), Kaplan--Meier survival method                    Delayed development of severe OM in OC only
  Ertekin et al^[@bibr29-1534735418794885]^                Radiotherapy                                    Zinc sulfate equiv 50 mg tid versus placebo                                                                                                                                                      HNC                               RCT (n = 21), RTOG                                              Decreased OM severity (*P* \< .05)
  Sangthawan et al^[@bibr30-1534735418794885]^             Radiotherapy                                    Zinc sulfate equiv 50 mg oral syrup versus placebo                                                                                                                                               HNC                               RCT (n = 104), WHO OMAS                                         NS benefit
  Arbabi-kalati et al^[@bibr31-1534735418794885]^          Chemotherapy                                    Zinc sulfate eqiv. 50 mg tid versus placebo                                                                                                                                                      HNC                               RCT (n = 50), WHO OMAS                                          Decreased OM severity (*P* \< .05)
  Mehdipour et al^[@bibr32-1534735418794885]^              Chemotherapy                                    0.2% zinc sulfate versus chlorhexidine gluconate mouthwashes                                                                                                                                     AML                               Comparative randomized (n = 30), Spijkervet scale               Decreased OM severity (*P* \< .05)
  Mansouri et al^[@bibr33-1534735418794885]^               HDC HSCT conditioning regimen                   Zinc sulfate equiv 50 mg bid versus placebo                                                                                                                                                      HM                                RCT (n = 60), WHO OMAS                                          NS benefit
  Hayashi et al^[@bibr34-1534735418794885]^                Radiotherapy or HDC HSCT conditioning regimen   Zinc sulfate/L-carnosine suspension or lozenge                                                                                                                                                   HSCT                              Comparative study (n = 66), CTCAE                               Decreased OM severity ⩾grade 2 (*P* \< .05) and decreased pain (*P* \< .01)
  Markiewicz et al^[@bibr35-1534735418794885]^             Radiotherapy HDC HSCT conditioning regimen      Calcium phosphate mouth rinse versus topical mouth care with sage extract, povidone-iodine, fluconazole, vitamin A (10 g), and vitamin E (10 g) with or without benzocaine (2.5 g) twice daily   AML/ALL                           NBCT (n = 40), WHO OMAS                                         Decreased OM severity (*P* \< .05) and decrease in pain NS
  Lambrecht et al^[@bibr36-1534735418794885]^              Chemotherapy and radiotherapy                   Calcium phosphate mouth rinse (Caphosol) versus standard oral care                                                                                                                               HNC                               RCT comparative (n = 58), CTCAE                                 NS OM grade 3
  Raphael et al^[@bibr37-1534735418794885]^                Chemotherapy or HSCT conditioning regimen       Calcium phosphate mouth rinse (Caphosol) versus standard oral care                                                                                                                               HM                                RCT (n = 34, pediatric), CTCAE                                  NS benefit
  Papas et al^[@bibr38-1534735418794885]^                  HDC HSCT conditioning regimen                   Calcium phosphate (Caphosol) versus fluoride mouth rinse                                                                                                                                         ALL/AML/CML/HL/NHL/MM/MS/BC/OvC   RCT comparative (n = 58), NIDCR                                 Decreased OM frequency/duration/severity (*P* \< .05)
  Madan et al^[@bibr39-1534735418794885]^                  Radiotherapy                                    1% povidone-iodine versus 0.12% chlorhexidine, sodium bicarbonate, plain water (control)                                                                                                         HNC                               RCT (n = 80), WHO OMAS                                          Decreased OM severity scores (*P* \< .05)
  Vokurka et al^[@bibr40-1534735418794885]^                HDC before PBSCT                                1% povidone-iodine mouthwash versus saline                                                                                                                                                       HSCT                              RCT multicenter (n = 132), WHO OMAS                             NS benefit
  Tsujimoto et al^[@bibr41-1534735418794885]^              Radiotherapy                                    Glutamine 30 g, oral/day versus placebo                                                                                                                                                          HNC                               RCT (n = 40), CTCAE                                             Decreased OM severity (*P* \< .05)
  Tanaka et al^[@bibr42-1534735418794885]^                 Radiotherapy                                    Glutamine 9 g with or without elemental diet versus placebo                                                                                                                                      HNC                               RCT (n = 40), CTCAE                                             Decreased OM severity (*P* \< .05)
  Huang et al^[@bibr43-1534735418794885]^                  Radiotherapy                                    Glutamine 30 g, oral/day versus saline                                                                                                                                                           HNC                               RCT (n = 17), WHO OMAS                                          NS benefit
  Vidal-Casariego et al^[@bibr44-1534735418794885]^        Radiotherapy                                    Glutamine 30 g oral/day versus late or no treatment                                                                                                                                              HNC/Mel/LC/OeC/Lym                Retrospective cohort (n = 117), WHO OMAS                        Decreased OM risk RR = −9.0% (95% CI = −18.0% to −1.0%)
  Jebb et al^[@bibr45-1534735418794885]^                   5-FU and folinic acid                           Glutamine 16 g oral/day versus placebo                                                                                                                                                           mCRC                              RCT (n = 28), WHO OMAS                                          NS benefit OM or IM
  Skubitz and Anderson^[@bibr46-1534735418794885]^         Chemotherapy                                    Glutamine 8 g oral/day                                                                                                                                                                           KS                                Open trial (n = 14), CALGB                                      Decreased OM severity (*P* \< .05)
  Anderson et al^[@bibr47-1534735418794885]^               Chemotherapy                                    Glutamine 4 g/m^2^/dose/day versus placebo                                                                                                                                                       Sar/NB                            RCT crossover study (pediatric n = 24), patient questionnaire   Decreased OM duration/severity (*P* \< .05)
  Okuno et al^[@bibr48-1534735418794885]^                  5-FU                                            Glutamine 30 g oral/day versus placebo                                                                                                                                                           Not defined                       RCT (n = 134), assessed by physician                            NS benefit
  Cockerham et al^[@bibr49-1534735418794885]^              Paclitaxel and melphalan                        Glutamine 24 g oral/day                                                                                                                                                                          mBC                               Retrospective analysis (n = 21), CTCAE                          Decreased OM days/severity (*P* \< .05)
  Dickson et al^[@bibr50-1534735418794885]^                HDC                                             Glutamine 30 g oral/day versus placebo                                                                                                                                                           ALL/AL/CML/MM/NHL                 RCT (n = 58), BMT scale                                         NS benefit OM and diarrhea
  Daniele et al^[@bibr51-1534735418794885]^                5-FU and follinic acid                          Glutamine, 18 g oral/day versus placebo                                                                                                                                                          mCRC                              RCT (n = 70), CTCAE                                             Decreased rescue meds (*P* \< .05)
  Cerchietti et al^[@bibr52-1534735418794885]^             Chemoradiotherapy                               L-Alanyl-L-glutamine, IV 300/400 mg/kg bw versus placebo                                                                                                                                         HNC                               RCT (n = 29), WHO OMAS                                          Decreased OM severity (NS) and decreased pain (*P* \< .05)
  Li et al^[@bibr53-1534735418794885]^                     Chemotherapy                                    Glutamine 30 g oral/day versus placebo                                                                                                                                                           BC                                RCT (n = 60), WHO OMAS                                          NS benefit OM or diarrhea
  Choi et al^[@bibr54-1534735418794885]^                   5-FU/leucovorin                                 Glutamine 10 g oral/day versus supportive care                                                                                                                                                   AST                               RCT (n = 51), CTCAE                                             Decreased OM severity (*P* \< .05)
  Peterson et al^[@bibr55-1534735418794885]^               Anthracycline chemotherapy                      Glutamine, 7.5 g oral/day versus placebo                                                                                                                                                         BC                                RCT crossover (n = 326), WHO OMAS                               Decreased OM severity grade 3 (*P* \< .05)
  *Oesophagitis*                                                                                                                                                                                                                                                                                                                                                                                              
  Topkan et al^[@bibr57-1534735418794885]^                 Radiotherapy                                    Glutamine 30 g oral/day versus no treatment                                                                                                                                                      LC                                Retrospective (n = 63), RTOG                                    Decreased grade 2-3 esophagitis (27.2%)
  Topkan et al^[@bibr56-1534735418794885]^                 Chemotherapy and radiotherapy                   Glutamine 30 g oral/day versus no treatment                                                                                                                                                      NSCLC                             RCT (n = 104), RTOG                                             Decreased grade 3 esophagitis (*P* \< .05)
  Tutanc et al^[@bibr58-1534735418794885]^                 Radiotherapy                                    Glutamine 30 g oral/day versus no treatment                                                                                                                                                      LC                                RCT (n = 46), RTOG                                              Decreased grade 2-3 esophagitis (*P* \< .05)
  Chattopadhyay et al^[@bibr59-1534735418794885]^          Radiotherapy                                    Glutamine 10 g oral/day versus no treatment                                                                                                                                                      HNC                               Randomized case-control study (n = 70), WHO OMAS                Decreased grade 2-3 esophagitis (*P* \< .05)
  Gul et al^[@bibr60-1534735418794885]^                    Radiotherapy                                    Glutamine 30 g oral/day versus no treatment                                                                                                                                                      LC                                RCT (n = 32), RTOG                                              Decreased esophagitis (*P* \< .05)
  *Intestinal mucositis/diarrhea clinical studies*                                                                                                                                                                                                                                                                                                                                                            
  Vidal-Casariego et al^[@bibr61-1534735418794885]^        Radiotherapy                                    Glutamine, 30 g, oral versus placebo                                                                                                                                                             AC/PC                             RCT (n = 69), RTOG                                              NS benefit on acute enteritis/diarrhea
  Michael et al^[@bibr13-1534735418794885]^                Irinotecan                                      Activated charcoal, 1000 mg                                                                                                                                                                      CRC                               Single-arm open-label (n = 24), CTCAE                           Decreased grade 3/4 diarrhea (7.1% vs 25%)

Abbreviations: CRC, colorectal cancer; CTCAE, Common Terminology Criteria for Adverse Events; OM, oral mucositis; HNC, head and neck cancer; OC, oral cancer; Tx, treatment; 5-FU, 5-fluorouracil; IM, intramuscular; NS, nonsignificant; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; RCT, randomized controlled trial; RTOG, Radiation Therapy Oncology Group; OeC, esophageal cancer; HCC, hepatocellular carcinoma; WHO OMAS, World Health Organization Oral Mucositis Assessment Scale; im, intramuscularly; OC, oral cancer; AL, acute leukemia; NHL, non-Hodgkin's lymphoma; HDC, high-dose chemotherapy; HSCT, hematopoietic stem cell transplantation; equiv, equivalent; NPC, nasopharyngeal carcinoma; tid, three times a day; bid, two times a day; HM, hematologic malignancies; HL, Hodgkin's lymphoma; MM, multiple myeloma; MS, myelodysplastic syndrome; BC, breast cancer; OvC, ovarian cancer; NIDCR, National Institute of Dental and Craniofacial Research; PBSCT, peripheral blood stem cell transplantation; Mel, melanoma; LC, lung carcinoma; Lym, lymphoma; RR, risk ratio; CI, confidence interval; mCRC, metastatic colorectal cancer; KS, Kaposi sarcoma; CALGB, Cancer and Leukemia Group B scale; Sar, sarcoma; NB, neuroblastoma; mBC, metastatic breast cancer; BMT, Stanford University Bone Marrow Transplant toxicity scale; IV, intravenous; bw, body weight; AST, aspartate aminotransferase; NSCLC, non--small cell lung cancer, AC, abdominal cancer; PC, pelvic cancer.

###### 

Clinical Trials Investigating Honey for Oral Mucositis.

![](10.1177_1534735418794885-table3)

  References                                            Interventions                                                                                                                                Cancer                                       Design; Assessment                                                                  Outcome
  ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  *Radiotherapy*                                                                                                                                                                                                                                                                                                                      
  Biswal et al^[@bibr64-1534735418794885]^              20 mL of honey 15 minutes before and after radiation versus standard oral care                                                               HNC                                          RCT (n = 40); RTOG                                                                  Decreased OM grade 3-4 (*P* \< .0005)
  Motallebnejad et al^[@bibr73-1534735418794885]^       20 mL of honey 15 minutes before and after radiation versus saline rinse                                                                     HNC                                          RSB (n = 40); WHO OMAS                                                              Decreased OM (*P* \< .05)
  Khanal et al^[@bibr70-1534735418794885]^              Swish honey for 2 minutes and expectorate, 20 mL versus lignocaine gel                                                                       OC                                           RSB (n = 40); RTOG                                                                  Decreased OM (*P* \< .05)
  Bardy et al^[@bibr63-1534735418794885]^               Manuka honey or placebo golden syrup 20 mL versus standard oral care                                                                         HNC                                          RCT (n = 131); RTOG                                                                 NS difference
  Jayachandran and Balaji^[@bibr68-1534735418794885]^   Honey versus benzydamine and saline                                                                                                          HNC                                          RCT (n = 60); WHO OMAS                                                              Decreased OM (*P* \< .05)
  Parsons et al^[@bibr85-1534735418794885]^             Manuka honey versus standard oral care                                                                                                       HCN                                          RCT (n = 28, 18 honey, 10 control); multisite mucositis scoring system              NS difference
  Charalambous et al^[@bibr82-1534735418794885]^        Honey versus saline rinse                                                                                                                    HCN                                          RCT (n = 30); RTOG                                                                  Grade 3 xerostomia RR = 0.13 and grade 3 oral mucositis RR = 0.26, indicating that honey is effective for both symptoms
  Alvi et al^[@bibr78-1534735418794885]^                20 mL honey versus saline rinse                                                                                                              HNC                                          RCT (n = 60); WHO OMAS                                                              Decreased OM (*P* \< .05)
  Hawley et al^[@bibr67-1534735418794885]^              Honey versus sugar-free gel                                                                                                                  HNC                                          RCT (n = 106); RTOG, WHO OMAS                                                       NS difference
  Samdariya et al^[@bibr76-1534735418794885]^           20 mL of honey before and after radiation and salt-soda and benzydamine mouth gargles versus salt-soda and benzydamine mouth gargles alone   HNC                                          RCT (n = 78); Visual Analogue Pain scale                                            Decreased severity pain score (*P* \< .05)
  Jayalekshmi et al^[@bibr69-1534735418794885]^         15 mL honey before and after radiation versus plain water rinse                                                                              HNC                                          RSB (n = 28); RTOG                                                                  Decreased OM (*P* \< .05)
  Rao et al^[@bibr86-1534735418794885]^                 Honey applied before and after radiation versus povidone-iodine                                                                              HNC                                          RSB (n = 50); RTOG                                                                  Decreased OM (*P* \< .002)
  Amanat et al^[@bibr80-1534735418794885]^              20 mL honey before and after radiation versus saline rinse                                                                                   HNC                                          RCT (n = 82); RTOG                                                                  Decreased OM grade 3 (*P* \< .016) and grade 4 (*P* \< .032)
  Fogh et al^[@bibr65-1534735418794885]^                10 mL liquid honey versus honey lozenge versus standard supportive care                                                                      Small and non--small cell lung cancer        RCT (n = 107, 53 supportive care, 54 liquid honey honey, 56 lozenge honey); CTCAE   Honey not superior to standard care
  *Chemotherapy*                                                                                                                                                                                                                                                                                                                      
  Abdulrhman et al^[@bibr62-1534735418794885]^          Honey versus honey, beeswax, olive oil, propolis mouthwash mixture versus standard oral care                                                 ALL                                          RCT pediatric, (n = 90); CTCAE                                                      Faster healing (*P* \< .05)
  Allenidekania^[@bibr77-1534735418794885]^             Honey versus chlorhexidine                                                                                                                   Pediatric cancer                             RCT (n = 23), WHO OMAS                                                              Decreased OM severity (*P* \< .001)
  Mishra and Nayak^[@bibr84-1534735418794885]^          Honey ice chips versus plain ice chips                                                                                                       ALL                                          RCT (n = 40); WHO OMAS                                                              Decreased OM occurrence (*P* \< .001) and no difference severity
  Kobya et al^[@bibr71-1534735418794885]^               Honey 1 g/kg daily versus standard oral care                                                                                                 HNC                                          Quasi-experimental study children multicenter (n = 83); WHO OMAS                    Decreased OM severity (*P* \< .05)
  *Chemoradiotherapy*                                                                                                                                                                                                                                                                                                                 
  Rashad et al^[@bibr75-1534735418794885]^              20 mL honey before and after radiation versus no honey                                                                                       HNC                                          RCT (n = 40); RTOG                                                                  Decreased OM grade 3-4 (*P* \< .05)
  Maiti et al^[@bibr72-1534735418794885]^               20 mL honey before and after radiation                                                                                                       HNC                                          RCT (n = 55); WHO OMAS                                                              Decreased OM grade 3-4 (*P* \< .05)
  Berk et al^[@bibr81-1534735418794885]^                Manuka honey liquid/lozenges versus supportive care                                                                                          LC                                           RCT (n = 163); CTCAE                                                                NS difference
  Raeessi et al^[@bibr74-1534735418794885]^             300 g of honey, or ±20 g of instant coffee versus topical betamethasone                                                                      HNC                                          RCT (n = 75); WHO OTS                                                               Decreased OM grade 3-4 (*P* \< .05)
  Francis and Williams^[@bibr66-1534735418794885]^      Honey mixed with turmeric powder versus standard care                                                                                        Various                                      Nonequivalent control group, pretest posttest design (n = 60), WHO OMAS             Decreased OM (*P* \< .05)
  Farneti et al^[@bibr83-1534735418794885]^             Sodium alginate, sodium carbonate, propolis, *Aloe vera*, calendula, honey, and chamomile versus placebo                                     HNC                                          RCT (n = 107), CTCAE                                                                NS difference
  Yadav^[@bibr87-1534735418794885]^                     Honey with glycerin versus standard care                                                                                                     HNC                                          RCT (n = 107), CTCAE                                                                Decreased OM (*P* \< .003)
  Al Jaouni et al^[@bibr79-1534735418794885]^           Honey versus standard oral care lidocaine, mycostatin)                                                                                       ALL, AML, Burkett's lymphoma, Wilm's tumor   Open, randomized trial (n = 40, pediatric), clinician defined OM assessment         Decreased OM grade 3-4 (*P* \< .02)

Abbreviations: HNC, head and neck cancer; RCT, randomized controlled trial; RTOG, Radiation Therapy Oncology Group Grading System; OM, oral mucositis; RSB, randomized single blinded; WHO OMAS, World Health Organisation Oral Mucositis Assessment Scale; OC, oral cancer; NS, nonsignificant; RR, risk ratio; CTCAE, Common Terminology Criteria for Adverse Events; ALL, acute lymphocytic leukemia; LC, lung carcinoma; WHO OTS, World Health Oraganization Oral Toxicity Scale; AML, acute myelogenous leukemia.

We also identified 19 probiotic studies ([Table 4](#table4-1534735418794885){ref-type="table"}).^[@bibr88-1534735418794885][@bibr89-1534735418794885][@bibr90-1534735418794885][@bibr91-1534735418794885][@bibr92-1534735418794885][@bibr93-1534735418794885][@bibr94-1534735418794885][@bibr95-1534735418794885][@bibr96-1534735418794885][@bibr97-1534735418794885][@bibr98-1534735418794885][@bibr99-1534735418794885][@bibr100-1534735418794885][@bibr101-1534735418794885][@bibr102-1534735418794885][@bibr103-1534735418794885][@bibr104-1534735418794885]-[@bibr105-1534735418794885]^ Nine placebo-controlled clinical trials^[@bibr88-1534735418794885][@bibr89-1534735418794885][@bibr90-1534735418794885][@bibr91-1534735418794885]-[@bibr92-1534735418794885],[@bibr95-1534735418794885][@bibr96-1534735418794885]-[@bibr97-1534735418794885],[@bibr106-1534735418794885]^ examined the prophylactic use of probiotic in intestinal mucositis induced by chemotherapy, radiotherapy, or a combination of both. Two trials did not include a comparator group.^[@bibr98-1534735418794885],[@bibr104-1534735418794885]^ Four studies examined the use of a probiotic in oral mucositis,^[@bibr99-1534735418794885],[@bibr100-1534735418794885],[@bibr103-1534735418794885],[@bibr105-1534735418794885]^ 3 studies were post-chemoradiotherapy treatment trials,^[@bibr93-1534735418794885],[@bibr94-1534735418794885],[@bibr101-1534735418794885]^ and 2 studies examined the febrile incidence during chemotherapy.^[@bibr102-1534735418794885]^

###### 

Clinical Trials Investigating Probiotics for Oral and Intestinal Mucositis/Diarrhea.

![](10.1177_1534735418794885-table4)

  References                                                                 Treatment                                                                      Intervention                                                                                                     Cancer Site                                                     Design                                          Outcomes
  -------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Oral mucositis clinical studies*                                                                                                                                                                                                                                                                                                                                                          
  Sharma et al^[@bibr99-1534735418794885]^                                   Radiotherapy plus cisplatin                                                    *L brevis* 2 × 10^9^ CFU, 6 lozenges versus placebo                                                              HNC                                                             RCT (n = 202), efficacy analysis = 188; CTCAE   Decreased incidence mucositis grade 3-4 and decreased completion of therapy (92% vs 70%; *P* \< .05)
  Sharma et al^[@bibr105-1534735418794885]^                                  HSCT                                                                           *L brevis* 2 × 10^9^ CFU, 3-4 lozenges, no control                                                               MM/HL/NHL/AML/RMS                                               Pilot, no control (n = 18); CTCAE               29% no mucositis, 19% grade 1 mucositis, 33% grade 2 mucositis, 9.5% grade 3-4 mucositis, and 65% \<grade 2 dysphagia
  Sharma et al^[@bibr100-1534735418794885]^                                  HSCT                                                                           *L brevis* 2 × 10^9^ CFU, 4-6 lozenges                                                                           CML/MM/HL/NHL/AML/RMS                                           Pilot, no control (n = 31); CTCAE               23% no mucositis, 19% grade 1 mucositis, 39% grade 2 mucositis, 13% grade 3 mucositis, and 7% grade 4 mucositis
  Giammarco et al^[@bibr103-1534735418794885]^                               HSCT                                                                           *L brevis* 2 × 10^9^ CFU, 6 lozenges versus OM prevention including chlorhexidine, saline rinses, and nystatin   MM                                                              RCT (n = 16); assessment method not specified   100% mucositis; NS difference between treatments (*P* \>.05)
  *Radiotherapy adverse events prevention studies*                                                                                                                                                                                                                                                                                                                                           
  Salminen et al^[@bibr97-1534735418794885]^                                 Pelvic radiotherapy, (internal and external) 80 Gy (tumor) and 50 Gy pelvis    *L acidophilus* NCDO 1748 + 6.5% lactulose, 2 × 10^11^ CFU qd versus dietary counselling                         Gynecological cancer                                            RCT (n = 24)                                    Significant reduction in incidence of diarrhea (*P* \< .01); RR = 0.3 (95% CI = 0.11-0.81); control group all with diarrhea
  Delia et al^[@bibr90-1534735418794885]^                                    Pelvic radiotherapy (60-70 Gy)                                                 VSL\#3 1 sachet tid versus placebo                                                                               Sigmoid rectal or cervical cancers                              RCT (n = 490)                                   Reduced incidence (124/239 \[51.8%\] and 77/243 \[31.6%\], *P* \< .001); reduced severity 55.4% and 1.4%, *P* \< .001); RR = 0.61 (95% CI = 0.45-0.76)
  Castro et al^[@bibr88-1534735418794885]^                                   Radiotherapy                                                                   *L casei* Shirota *B breve* (strain and dose not provided) versus placebo                                        Prostate cancer                                                 RCT (n = 40)                                    Reduction in proctitis; improved QoL; RR = 0.54 (95% CI = 0.27-1.06)
  Demers et al^[@bibr91-1534735418794885]^                                   Pelvic radiotherapy (44 Gy)                                                    *L acidophilus* LAC-361, *B longum* BB536, 1.3 × 10^11^ CFU bid standard dose versus high dose versus placebo    Cervical and uterine cancers                                    RCT (n = 229)                                   Reduced incidence grade 4 diarrhea; standard dose; RR = 1.09 (95% CI = 0.76-1.59)
  *Chemotherapy adverse events prevention studies*                                                                                                                                                                                                                                                                                                                                           
  Österlund et al^[@bibr96-1534735418794885]^                                5-FU and leucovorin                                                            *L rhamnosus* GG, 1-2 × 10^11^ CFU + 11 g guar gum qd versus no prophylactic treatment                           Colorectal cancer                                               RCT (n = 150)                                   Reduced grade 3 or 4 diarrhea (22% vs 37%, *P* = .027); reduced abdominal discomfort; reduced hospital care; fewer chemotherapy dose reductions due to bowel toxicity; RR = 0.58 (95% CI = 0.35-0.98)
  Sharma et al^[@bibr106-1534735418794885]^                                  Irinotecan and/or fluoropyrimidines                                            VSL\#3 1 sachet bid versus placebo                                                                               Not defined                                                     RCT (n = 202)                                   No significant difference in incidence of diarrhea; RR = 2.76 (95% CI 0.89-8.51)
  Mego et al^[@bibr95-1534735418794885]^                                     Irinotecan                                                                     Colon Dophilus 10 × 10^9^ capsules CFU tid versus placebo                                                        Colorectal cancer                                               RCT (n = 46)                                    Reduction grade 3 or 4 diarrhea (0% vs 17.4%, *P* = .11); reduced overall incidence of diarrhea (39.1% vs 60.9%, *P* = .24); reduced incidence of enterocolitis (0% vs 8.7%) RR = 0.1 (95% CI = 0.006-1.95)
  *Chemoradiotherapy adverse events prevention studies*                                                                                                                                                                                                                                                                                                                                      
  Giralt et al^[@bibr92-1534735418794885]^                                   Pelvic radiotherapy (45-50 Gy), weekly cisplatin 40 mg/m^2^                    96 mL fermented yogurt with *L casei* DN11400, 1.1 × 10^11^ CFU/g yogurt tid versus placebo                      Cervical squamous cell carcinoma; endometrial adenocarcionoma   RCT (n = 85)                                    Improved stool consistency (*P* = .04); no difference to presentation of end point (diarrhea) or use of loperamide; RR = 1.17 (95% CI = 0.84-1.62)
  Chitapanarux et al^[@bibr89-1534735418794885]^                             Radiotherapy and cisplatin                                                     500 mg Infloran bid versus placebo                                                                               Cervical cancer (local advanced)                                RCT (n = 63)                                    45% grade 2-3 diarrhea placebo group and 9% of probiotic group (*P* = .002); antidiarrheal medications reduced (*P* = .03); improved stool consistency (*P* \< .001) respectively; RR = 0.21 (95% CI = 0.07-0.65)
  *Radiotherapy adverse effects prevention studies (no comparator groups)*                                                                                                                                                                                                                                                                                                                   
  Timko^[@bibr104-1534735418794885]^                                         Radiotherapy 50-67 Gy abdomen/pelvis                                           Colon Dophilus 2 capsules qd                                                                                     Abdominal and pelvis cancers                                    RNB (n = 42), stool diary                       Reduction in diarrhea and antibiotic use
  Scartoni et al^[@bibr98-1534735418794885]^                                 Radiotherapy 30-80 Gy pelvis                                                   Dixentil 10 mL vial qd                                                                                           Large bowel urological, gynecological cancers                   Prevention/safety (n = 42)                      Reduction in diarrhea
  *Radiotherapy treatment studies*                                                                                                                                                                                                                                                                                                                                                           
  Henriksson et al^[@bibr93-1534735418794885]^                               Radiotherapy 62-66 Gy pelvis                                                   Fermented milk, *L lactis, L diacetylactis, L cremoris* versus nonactive fermented milk                          Pelvis and urinary bladder cancers                              RCT (n = 40), stool diary                       Reduction in chronic bowel discomfort
  Urbancsek et al^[@bibr101-1534735418794885]^                               Radiotherapy to 50 Gy abdomen                                                  *L rhamnosus* 1.5 × 10^11^ CFU 4 weeks post radiotherapy versus placebo                                          Pelvis and abdominal cancers                                    RCT (n = 206), stool diary                      Reduction in self-ratings diarrhea grade and feces consistency (*P* \< .05)
  Lee et al^[@bibr94-1534735418794885]^                                      Radiotherapy and chemotherapy 6 weeks to 2 years prior to enrolment in study   Lacidofil with *L rhamnosus* R0011, *L acidophilus* R0052, 2 × 10^11^ CFU 2 capsules qd versus placebo           Colorectal cancers                                              RCT (n = 60); Rome III; stool diary             Decreased IBS (*P* \< .05); increase in functional health scores (*P* \< .05); increased FACT scores (*P* \< .05)
  *Clinical trials investigating infectious complications*                                                                                                                                                                                                                                                                                                                                   
  Wada et al^[@bibr102-1534735418794885]^                                    Chemotherapy not further defined                                               *B breve* M-16-V, 1 × 10^11^ CFU qd                                                                              Not defined                                                     RNB (n = 42)/pediatric                          Reduction in febrile episodes, antibiotic use; no effect on diarrhea; no difference in WBC or NK cells

Abbreviations: CFU, colony-forming unit; HNC, head and neck cancer; RCT, randomized controlled trial; CTCAE, Common Terminology Criteria for Adverse Events; HSCT, hematopoietic stem cell transplantation; MM, multiple myeloma; HL, Hodgkin's lymphoma; NHL, non-Hodgkin's lymphoma; AML, acute myelogenous leukemia; RMS, rhabdomyosarcoma; CML, chronic myelogenous leukemia; OM, oral mucositis; NS, nonsignificant; qd, one a day; RR, risk ratio; CI, confidence interval; NK, natural killer; VSL\#3, *L casei, L plantarum, L acidophilus, L delbruekii* subsp *bulgaricus, B longum, B breve, B infantis, Streptococcus salivarius* subsp *thermophiles*; Colon Dophilus, *B breve* HA-129 (25%), *B bifidum* HA-132 HA (20%), *B longum* HA-135 (14.5%), *L rhamnosus* HA-111 (8%), *L acidophilus* HA-122 (8%), *L casei* HA-108 (8%), *L plantarum* HA-119 (8%), *S thermopilus* HA-110 (6%), *L brevis* HA-112 (2%), *B infantis* HA-116; Infloran, 1 billion viv Lyophilisat and 1 billion *B bifidum* viv Lyophilisat; Dixentil, *L acidophilus* and *L casei* (strains not provided), zinc, galacto-oligosaccharides, and vitamins B~1~/B~2~/B~6~ and nicotinamide; tid, three times a day; QOL, quality of life; bid, two times a day; 5-FU, 5-fluorouracil; RNB, randomized nonblinded; IBS, irritable bowel syndrome; FACT, Functional Assessment of Cancer Therapy; WBC, white blood cells.

Oral mucositis was most commonly assessed according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer objective grading system (RTOG/EORTC), the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), or the World Health Organization Oral Mucositis Toxicity Scale. Intestinal mucositis was assessed by changes in stool consistency, incidence and severity of diarrhea, and the use of antidiarrheal medication. The most frequently used assessment scales are the CTCAE diarrhea grade and the Bristol stool charting system.

Bias and quality analysis were not performed as part of this review, as several reviews have already reported on bias and quality of studies for minerals, glutamine, honey, and probiotics, the 4 types of interventions with sufficient number of trials to attempt conducting a systematic review or meta-analysis. Although some studies had low bias, the overall assessment is that many studies have high bias and most studies suffered from some methodological weaknesses.^[@bibr107-1534735418794885][@bibr108-1534735418794885][@bibr109-1534735418794885][@bibr110-1534735418794885][@bibr111-1534735418794885]-[@bibr112-1534735418794885]^ The systematic review and meta-analysis of 9 probiotic trials for the prevention of chemoradiotherapy-induced diarrhea found that while the trials were of generally good methodological quality, there were significant blinding issues, and 1 study was published as a poster abstract only. Ambiguous handling of incomplete outcome data and lack of intention-to-treat analysis were noted as further bias risks.^[@bibr112-1534735418794885]^

Reviewed Interventions {#section4-1534735418794885}
----------------------

Prophylactic *activated charcoal* has been shown to reduce dose-limiting chemotherapy-induced diarrhea, thereby optimizing irinotecan therapy, while reducing antidiarrheal medication in an open-label, single-arm study. The study involved 28 patients with advanced CRC receiving irinotecan 125 mg/m^2^ intravenously once a week for 4 weeks every 6 weeks. In cycle 1, patients received irinotecan plus activated charcoal (5 mL aqueous solution containing 1000 mg activated charcoal in 25 mL of water), given the evening before the irinotecan dose and then 3 times daily for 48 hours after the dose. The use of activated charcoal in the first cycle was associated with a significant reduction in the incidence and severity of diarrhea, reduced the use of loperamide as a rescue medication, and was well tolerated with excellent compliance^[@bibr13-1534735418794885]^ ([Table 2](#table2-1534735418794885){ref-type="table"}).

*Beta-glucan* is an immune-modulating polysaccharide that was shown in a retrospective, controlled trial of 62 patients with CRC to prevent significant reductions in leucocyte and neutrophil counts compared with chemotherapy alone with a FOLFOX-4 regimen. The addition of β-glucan was also associated with a lower incidence of oral mucositis and diarrhea ([Table 2](#table2-1534735418794885){ref-type="table"}).^[@bibr14-1534735418794885]^

Concurrent administration of *folate* and *cobalamin* failed to reduce mucositis in a pilot study of 39 patients with non--small cell lung cancer treated with pralatrexate. Mucositis remained the dose-limiting toxicity of pralatrexate treatment^[@bibr19-1534735418794885]^ ([Table 2](#table2-1534735418794885){ref-type="table"}).

A meta-analysis that assessed the effectiveness of oral *glutamine* in radiotherapy-induced mucositis in head and neck cancers reported that in 5 clinical studies (234 patients total),^[@bibr41-1534735418794885],[@bibr43-1534735418794885],[@bibr44-1534735418794885],[@bibr52-1534735418794885],[@bibr59-1534735418794885]^ glutamine was shown to reduce the risk and severity of radiotherapy-induced oral mucositis compared with either placebo or no treatment (risk ratio \[RR\] = 0.17, 95% confidence interval \[CI\] = 0.06-0.47).^[@bibr107-1534735418794885]^ Oral glutamine was also shown to be beneficial in 11^[@bibr41-1534735418794885],[@bibr44-1534735418794885],[@bibr46-1534735418794885],[@bibr49-1534735418794885],[@bibr54-1534735418794885][@bibr55-1534735418794885][@bibr56-1534735418794885][@bibr57-1534735418794885][@bibr58-1534735418794885][@bibr59-1534735418794885]-[@bibr60-1534735418794885]^ of 15 studies investigated in a systematic review investigating the effects of glutamine for chemotherapy- or radiotherapy-induced oral mucositis. Glutamine significantly reduced the incidence of grade 2, 3, or 4 mucositis and/or reduced weight loss as well as the duration, time of onset, and/or maximum grade of mucositis.^[@bibr108-1534735418794885]^ Four studies showed no effect^[@bibr45-1534735418794885],[@bibr48-1534735418794885],[@bibr50-1534735418794885],[@bibr53-1534735418794885]^ ([Table 2](#table2-1534735418794885){ref-type="table"}).

A recent study found that 9 g glutamine in combination with an elemental diet was associated with a significant reduction in chemotherapy-induced oral mucositis in esophageal cancer compared with no treatment or glutamine alone. The incidence of grade 2 or higher of oral mucositis was 60% in the control group, 70% in the glutamine group, and 10% in the glutamine plus elemental diet group.^[@bibr42-1534735418794885]^ A further review of 9 randomized, controlled studies concluded that glutamine may reduce gastrointestinal mucositis and diarrhea and improve nitrogen balance, immune imbalance, and wound healing in chemotherapy-induced toxicity^[@bibr113-1534735418794885]^ ([Table 2](#table2-1534735418794885){ref-type="table"}).

Glutamine has been shown to be a principal nutrient with glucose supporting survival of mammalian cells and, unfavorably, cancer cells. However, oral glutamine has been reported to be unlikely to contribute significantly to tumor growth, local invasion, and metastatic dissemination.^[@bibr114-1534735418794885]^ High baseline consumption of dietary glutamate has been shown in humans to be associated with a lower risk for CRC,^[@bibr115-1534735418794885]^ and oral glutamine 2 days before tumor implantation has been shown in rodents to increase natural killer cell activity, upregulate intestinal glutathione metabolism, and decrease tumor growth by 40% to 50%.^[@bibr116-1534735418794885],[@bibr117-1534735418794885]^ Oral glutamine administered during chemoradiotherapy did not negatively affect tumor control and survival in patients with stage IIIB non--small cell lung cancer.^[@bibr56-1534735418794885]^ As cancer cells can manipulate host metabolism favoring tumor growth, deprivation of dietary glutamine or the use of oral supplementation for mucositis was reported unlikely to adversely affect tumor growth during chemotherapy treatments. Glutamine, however, has been shown to be ineffective in controlling acute radiation-induced intestinal mucositis.^[@bibr61-1534735418794885],[@bibr118-1534735418794885]^

A Cochrane review of 3 studies^[@bibr64-1534735418794885],[@bibr73-1534735418794885],[@bibr75-1534735418794885]^ investigating *honey* concluded that it was associated with a weak to moderate benefit in the prevention of radiotherapy-induced oral mucositis.^[@bibr119-1534735418794885]^ Three subsequent meta-analyses concluded that oral administration of honey could prevent the incidence of radiotherapy-induced oral mucositis in head and neck cancers.^[@bibr109-1534735418794885],[@bibr110-1534735418794885],[@bibr120-1534735418794885]^ Cho et al concluded that oral administration of honey after radiotherapy could prevent the development of moderate to severe mucositis and associated weight loss.^[@bibr109-1534735418794885]^ Xu et al concluded that, compared with no treatment, honey could reduce the incidence of oral mucositis after chemoradiotherapy (RR = 0.35, 95% CI = 0.18-0.70, *P* = .003).^[@bibr110-1534735418794885]^ Honey was also found to decrease treatment interruptions, weight loss, and delay the onset of oral mucositis. Honey, however, was inefficacious in decreasing the peak mucositis score. Co et al reported statistical pooling showing that the risk ratio of having a treatment interruption was significantly lower with the use of honey versus control 0.11 (95% CI = 0.02-0.58) with a risk ratio of developing severe mucositis when honey was administered as 0.45 with a CI of 0.09 to 2.21.^[@bibr120-1534735418794885]^

Friend et al specifically examined pediatric trials and identified 4 trials^[@bibr62-1534735418794885],[@bibr71-1534735418794885],[@bibr77-1534735418794885],[@bibr79-1534735418794885]^ with grade C evidence that honey was effective as a preventative and adjunctive therapy for chemotherapy-induced oral mucositis in children.^[@bibr121-1534735418794885]^ Honey was found to reduce the frequency, duration, and stage of chemotherapy-induced mucositis.

Seven trials have been published since the meta-analyses report.^[@bibr109-1534735418794885],[@bibr110-1534735418794885],[@bibr120-1534735418794885]^ Four trials examined honey in radiotherapy-induced mucositis in head/neck and lung cancers,^[@bibr65-1534735418794885],[@bibr69-1534735418794885],[@bibr80-1534735418794885],[@bibr86-1534735418794885]^ 1 trial in chemotherapy-induced mucositis in acute lymphocytic leukemia,^[@bibr84-1534735418794885]^ and 2 trials in chemoradiotherapy-induced mucositis in children with various cancers.^[@bibr79-1534735418794885],[@bibr87-1534735418794885]^ Only one trial^[@bibr65-1534735418794885]^ reported no effect. Medical manuka honey administered as a liquid or as a lozenge was not superior to best supportive care in preventing radiation esophagitis.^[@bibr65-1534735418794885]^

A single-blinded randomized controlled trial (n = 28) found that 15 mL of natural honey was associated with a statistically significant difference in degree of oral mucositis between the experimental and control groups in weeks 4, 5, and 6 (*P* \< .01).^[@bibr69-1534735418794885]^ Compared with the active comparator, povidone-iodine, honey significantly reduced radiation-induced oral mucositis, decreased the incidence of intolerable mucositis, treatment breaks, loss of treatment days (*P* \< .0001 and \< .0003), and did not affect the radiation-induced tumor response.^[@bibr86-1534735418794885]^ Honey significantly reduced the severity of mucositis (grades 3 and 4) compared with control group at the end of 6 weeks of radiation treatment.^[@bibr80-1534735418794885]^ Honey ice cubes were shown to significantly reduce the occurrence of chemotherapy-induced oral mucositis in pediatric cancer patients compared with plain ice cubes on the 5th (*P* = .001) and 15th (*P* = .001) days of assessment.^[@bibr84-1534735418794885]^ A significantly higher number of patients developed grade 2 or above chemoradiotherapy-induced mucositis in the control arm compared with the experimental arm (*P* = .003).^[@bibr87-1534735418794885]^ Absolute risk reduction between honey and control for developing grades III and IV oral mucositis was found to be significant in a study of pediatric cancer patients receiving chemoradiotherapy (*P* \< .05^[@bibr79-1534735418794885]^; [Table 3](#table3-1534735418794885){ref-type="table"}).

A meta-analysis of randomized controlled trials (RCTs) examining oral mucositis induced by chemoradiotherapy, or hematopoietic stem cell transplantation (HSCT), found that patients pretreated with *mineral supplementation* delayed the onset of mucositis and that fewer patients experienced less peak oral mucositis compared with controls.^[@bibr111-1534735418794885]^ The analysis examined 7 studies with zinc,^[@bibr26-1534735418794885][@bibr27-1534735418794885][@bibr28-1534735418794885][@bibr29-1534735418794885][@bibr30-1534735418794885]-[@bibr31-1534735418794885],[@bibr33-1534735418794885]^ 3 with calcium,^[@bibr36-1534735418794885][@bibr37-1534735418794885]-[@bibr38-1534735418794885]^ 2 with selenium,^[@bibr24-1534735418794885],[@bibr25-1534735418794885]^ and 2 with iodine.^[@bibr39-1534735418794885],[@bibr40-1534735418794885]^ Significant study bias was observed though and study heterogeneity, making it difficult to make specific clinical recommendations. Mineral formulations did not overall significantly reduce mean duration of mucositis, pain duration, or use of analgesics.^[@bibr111-1534735418794885]^ Of the 14 studies included in the meta-analysis, the 3 excluded^[@bibr26-1534735418794885],[@bibr32-1534735418794885],[@bibr122-1534735418794885]^ and 2 recent studies^[@bibr34-1534735418794885],[@bibr98-1534735418794885]^ are presented in [Table 2](#table2-1534735418794885){ref-type="table"}. Zinc is essential for proper immune function and for the integrity of connective tissue and cell membranes, and 50 to 150 mg elemental zinc daily was reported to reduce oral mucositis^[@bibr27-1534735418794885][@bibr28-1534735418794885]-[@bibr29-1534735418794885],[@bibr31-1534735418794885]^ ([Table 2](#table2-1534735418794885){ref-type="table"}).

Four studies examining the effects of *multinutrient formulations* that consisted of a mixture of open-label, retrospective, and prospective studies were identified. In a small, open-label study, it was reported that oral or parenteral administration of a multinutrient formulation was well tolerated in patients with head and neck cancers treated with chemoradiotherapy without developing severe mucositis.^[@bibr15-1534735418794885]^ In another, multinutrient formulation composed of amino acids, omega-3 fatty acids, ribonucleic acids, vitamins, and antioxidants was shown to be associated with less severe mucositis in patients with head and neck cancers treated with chemoradiotherapy.^[@bibr16-1534735418794885]^ In 2 other studies that examined the same amino acid--rich oral formulation, the first study found that the formulation was associated with reduced severity of mucositis in squamous cell carcinoma treated with radiotherapy with or without chemotherapy when compared with no formulation administration. The nutrient formulation was also associated with improved completion rates of chemoradiotherapy.^[@bibr17-1534735418794885]^ The second study was a prospective pilot study in CRC treated with 5-FU-based chemotherapy. This study reported that the multinutrient formulation was associated with a decrease in the severity of oral mucositis in approximately 90% of the patients during the first course of treatment (*P* = .0002) and maintained in the second course of treatment (*P* \<.0001^[@bibr18-1534735418794885]^; [Table 2](#table2-1534735418794885){ref-type="table"}).

*Vitamin E* may reduce mucositis by regulating nrf2 activation. Gamma-tocotrienol has been shown to prevent 5-FU-induced redox signaling by regulating nrf2 activation and cell survival in human oral keratinocytes.^[@bibr123-1534735418794885]^ Applying vitamin E directly to the mucous membranes may be more effective than orally administered. Oral vitamin E (400 mg twice daily) was shown to have no effect on the incidence or severity of mucositis in an RCT of 60 patients with leukemia receiving allogenic bone marrow transplantation.^[@bibr12-1534735418794885]^ Despite this, topical vitamin E was shown to be beneficial in the treatment of oral lesions associated with mucositis in an RCT of patients with solid tumors (n = 17) or leukemia (n = 1). Six of 9 patients receiving vitamin E had complete resolution of oral lesions compared with 1 out of 9 in the control group (*P* = .025).^[@bibr21-1534735418794885]^ In another study with 80 patients who developed oral mucositis, 100 mg of a topical, but not oral, application of vitamin E was shown to improve mucositis.^[@bibr22-1534735418794885]^ In a further study with 54 patients with head and neck cancers it was found that vitamin E before, and for the duration of radiotherapy, decreased the incidence of mucositis.^[@bibr20-1534735418794885]^ Topical vitamin E reduced the risk of mucositis by 36%.^[@bibr20-1534735418794885]^ Both topically applied vitamin E and the oligomeric procyanidin known as pycnogenol were shown in an RCT to reduce mucositis in 72 children although pycnogenol was not effective for severe, grade 4 mucositis^[@bibr23-1534735418794885]^ ([Table 2](#table2-1534735418794885){ref-type="table"}).

A *probiotic* containing lozenge, specifically with *Lactobacillus brevis*, has been shown in an RCT to reduce radiation- and chemotherapy-induced oral mucositis in 200 patients with head and neck cancers. Use of the probiotic was associated with a reduced incidence of mucositis grades III and IV (*P* = .001). Supportive treatment with the probiotic was administered during treatment and for 1 week post treatment completion (radiotherapy and weekly cisplatin).^[@bibr99-1534735418794885]^ The same probiotic lozenge formulation was also examined in 3 studies of patients undergoing HSCT for a variety of cancers including multiple myeloma. In the first pilot study, of 21 patients, only 19% developed grade III or IV mucositis compared with the expected 60%. No adverse events except occasional grade I/II nausea due to study drug were noted.^[@bibr105-1534735418794885]^ The second pilot study by the same research group found that 20% developed grade III or IV mucositis.^[@bibr100-1534735418794885]^ In a repeat pilot study, patients treated with HSCT were given the probiotic lozenge 4 to 7 days before initiation of chemotherapy and continuing until resolution of mucositis or till day 24. The single-arm, single-center, phase II study found that of the 31 patients enrolled, 7 (22.6%) patients did not develop any mucositis, 6 (19.4%) patients developed grade 1 mucositis, 12 (38.7%) patients developed grade 2 mucositis, and 4 (12.9%) and 2 (6.5%) patients developed grade 3 and grade 4 mucositis, respectively. Median time to onset and for resolution of mucositis was 6 days and 8 days, respectively. No adverse events were reported with usage of study drug.^[@bibr100-1534735418794885]^ However, in the fourth pilot study by another group using the same formulation in patients undergoing HSCT, all 16 patients developed various grades of mucositis with no statistical difference between the probiotic lozenge and standard treatment^[@bibr103-1534735418794885]^ ([Table 4](#table4-1534735418794885){ref-type="table"}).

The majority of studies investigated the prophylactic use of probiotics for diarrhea, while a few investigated the efficacy of probiotics in the treatment of irritable bowel syndrome or diarrhea, weeks to years post treatment ([Table 4](#table4-1534735418794885){ref-type="table"}). The studies used a variety of probiotic interventions and protocol designs and outcomes, making it difficult to identify which type of intervention and protocol was most beneficial. A systematic review and meta-analysis of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancers found that probiotics were generally beneficial in treatment-induced diarrhea, especially for grades 2 and 3.^[@bibr112-1534735418794885]^ A recent meta-analysis that grouped 7 studies for the prophylactic use of probiotics for cancer therapy--induced diarrhea^[@bibr124-1534735418794885]^ concluded that current evidence does not support widespread implementation of probiotics for the management of diarrhea secondary to cytotoxic therapy and the tyrosine kinase inhibitor, dacomitinib. The administration of probiotic was begun on the first day of cancer therapy initiation and as such referring to prophylactic interventions may be inaccurate. The administration of prophylactic probiotics must begin ideally 1 month prior to chemotherapy/radiotherapy initiation.

In order to investigate the probiotic effect to reduce diarrhea induced by chemotherapy and/or radiotherapy, relative risks were calculated for the 9 RCTs, and the results showed that 7 studies favored probiotics for preventing chemotherapy- and/or radiotherapy-induced grade ⩾2 diarrhea ([Figure 1](#fig1-1534735418794885){ref-type="fig"}). The co-administration of probiotics with radiotherapy shows enhanced efficacy in preventing intestinal adverse effects induced by radiotherapy compared with chemotherapy.

![Forest plot of RCTs of chemotherapy-/radiotherapy-induced diarrhea.\
RCT, randomized controlled trials; RT, radiotherapy; CT, chemotherapy; CRT, chemoradiotherapy; RR, relative risk, risk ratio.](10.1177_1534735418794885-fig1){#fig1-1534735418794885}

Adjuvant Interventions Safety {#section5-1534735418794885}
-----------------------------

One study implementing manuka honey mouthwash found that while it demonstrated benefit in ameliorating radiation-induced weight loss and increase quality of life in the absence of cisplatin chemotherapy, it was also reported that undiluted manuka honey caused severe nausea, vomiting, and severe stinging.^[@bibr85-1534735418794885]^ In an additional study, Bardy et al found no difference between golden syrup and manuka honey,^[@bibr63-1534735418794885]^ suggesting that perhaps the high sucrose content was responsible for the antibacterial effect observed. Neither study showed improvement in mucositis; however, compliance associated with the taste and texture of the interventions was an issue, which may have influenced the study outcome.

The common dose administered in clinical trials was 20 mL of honey, 3 times daily. At this dose, honey did not affect blood sugar levels when initial fasting blood sugar level was below 150 mg/dL.^[@bibr72-1534735418794885]^ Patients undergoing radiotherapy for head and neck cancers have been reported to be prone to a range of dental complications,^[@bibr125-1534735418794885]^ and a concern was the added risk of developing dental caries, in spite of research suggesting otherwise.^[@bibr126-1534735418794885]^ Radiation-related caries are related to hyposalivation, shifts in the oral microbiota, and altered saliva composition. The rapid onset and progression often leads to extensive loss of dentition within short periods of time. Honey contains known cariogenic substances including glucose, fructose, sucrose, and numerous acids, including gluconic, acetic, lactic, butyric, and formic acids, that may contribute to cariogenic increased risk.^[@bibr127-1534735418794885]^ However, honey has also been shown to prevent radiation-induced decrease enamel microhardness in xerostomic patients compared with patients with normal salvia.^[@bibr128-1534735418794885]^ None of the trials reported that the use of honey predisposed to the development of caries.

The use of probiotics as an adjunctive medicine in oncology to enhance treatment or reduce adverse events associated with chemotherapy or radiotherapy is not part of standard practice. The principal concern being that patients treated with chemotherapy are frequently immune-compromised and, therefore, are at increased risk of sepsis from administering probiotic formulations. A systematic review of 17 studies (N = 1530) found no reports of significant side effects such as serious localized or systemic infections when administered to patients receiving cancer treatments. Five case reports showed probiotic-related bacteremia, fungemia, or positive blood cultures.^[@bibr129-1534735418794885]^ Wang et al included 11 studies in its safety analysis. Seven studies did not report any adverse events. Four studies reported various adverse events. The reporting of adverse effects was, however, very inconsistent and poorly documented. Although some infections were reported, no probiotic bacteria growth could be found in blood cultures. Other adverse effects included mild gastrointestinal upsets, fever, and anorexia, which were also observed in the control groups.^[@bibr112-1534735418794885]^ Okawa et al reported 1 death but no evidence of an association with the probiotic intervention was reported.^[@bibr130-1534735418794885]^ A few probiotic trials have been performed in children.^[@bibr102-1534735418794885],[@bibr131-1534735418794885]^ A single-blinded study found that *Bifidobacterium breve* reduced the frequency of fever, which was associated with a lower use of intravenous antibiotics compared with placebo in children receiving chemotherapy (1-13 years of age, n = 42). No adverse events were reported.^[@bibr102-1534735418794885]^ A safety and feasibility study did not report *Lactobacillus plantarum*--associated bacteremia in children undergoing allogenic hematopoietic cell transplant;^[@bibr131-1534735418794885]^ however, a case of septic shock caused by yogurt-derived *Lactobacillus* species was recently reported in a 54-year-old male patient with acute promyelocytic leukemia. The bacteremia developed a week after the patient underwent high-dose chemotherapy and autologous peripheral blood stem cell transplantation. The pathogen was identified by strain-specific polymerase chain reaction analysis to be identical to the *Lactobacillus rhamnosus* GG found in the yogurt.^[@bibr132-1534735418794885]^

Discussion {#section6-1534735418794885}
==========

Recent interventions have continued to explore and to further build the scientific and clinical understanding of oral and intestinal mucositis preventative and treatment options that may be available to clinicians and patients.^[@bibr13-1534735418794885],[@bibr112-1534735418794885],[@bibr121-1534735418794885],[@bibr133-1534735418794885]^ The prevention and treatment of oral and intestinal mucositis that seeks to decrease the risk of formation and/or progression of these deleterious sequela of chemoradiotherapy regimens are important factors that impinge on patient quality of life and clinical decisions relevant to treatment. While it is acknowledged that oral and intestinal mucositis represent significant burdens of antineoplasitic therapies, the implementation of adjunctive treatments still remain a challenge.^[@bibr134-1534735418794885]^

Chemotherapy and radiotherapy have significant adverse effects on the microbiota of the oral and gastrointestinal mucosa. Oral mucositis is strongly associated with bacteremia and sepsis due to *Escherichia coli, Pseudomonas aeruginosa*, and *Candida albicans.*^[@bibr103-1534735418794885]^ How probiotics were postulated to overcome the side effects of chemotherapy and/or radiotherapy was advanced from observations that *Lactobacillus brevis*--containing lozenges produced anti-inflammatory metabolites.^[@bibr103-1534735418794885]^ It was reported that *L brevis* produced arginine deiminase and sphingomyelinase, which hydrolyses platelet-activating factor known to be associated with oral mucositis in radiation therapy.^[@bibr103-1534735418794885]^ Arginine deiminase then converts arginine to ammonia and citrulline, reducing the amount of available arginine to be converted to nitric oxide---a major mediator of inflammation. Furthermore, the appeal of probiotics administered for oral mucositis was enhanced when they were demonstrated to have no serious adverse effects.^[@bibr99-1534735418794885],[@bibr103-1534735418794885],[@bibr105-1534735418794885]^ This local oral benefit did not, however, extend to the intestines, with 14 out of 16 patients developing diarrhea.^[@bibr103-1534735418794885]^

In the intestines, cancer therapy has been found to decrease commensals such as *Bifidobacteria, Clostridium* cluster XIVa, and *Faecalibacterium prausnitzii*, combined with increases in *Enterobacteriaceae* and *Bacteroides*. These changes induce intestinal dysbiosis and contribute to the development of mucositis, particularly diarrhea and bacteremia.^[@bibr135-1534735418794885]^ Adverse shifts in the intestinal microbiota has led to the notion that the administration of probiotics could reduce the side effects of chemotherapy and radiotherapy.

There is moderate evidence that zinc, selenium, vitamin E, glutamine, and honey may be beneficial for the prevention or treatment of oral mucositis. However, the low numbers and heterogeneity of the studies reviewed generally makes it difficult to offer specific clinical recommendations. In one review, mineral supplementation, including zinc, did not overall significantly reduce mean duration of the mucositis, pain incidences, or use of analgesics.^[@bibr111-1534735418794885]^ The recommendation for zinc supplementation is currently restricted for patients with oral cancer having treatment with chemotherapy or radiation according to the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) guidelines. One drawback of using zinc supplementation is that it may induce nausea and even vomiting. Zinc supplementation should not be taken on an empty stomach, as it increases the adverse effects. The studies mostly used 220 mg zinc sulfate, equivalent to 50 mg elemental zinc, 2 to 3 times daily as a mouthwash or capsule/tablet.

The administration of selenium in clinical studies employed doses that ranged from 200 µg elemental selenium twice daily^[@bibr25-1534735418794885]^ to sodium selenite oral fluid 200 to 500 µg an hour prior to radiotherapy sessions.^[@bibr24-1534735418794885]^ Applying vitamin E directly to the oral mucosa may be more effective than orally administered.

Glutamine was found to be the most studied nutritional intervention and despite evidence suggesting that glutamine may reduce gastrointestinal mucositis and chemotherapy-induced diarrhea, the European Society for Clinical Nutrition and Metabolism (ESPEN)^[@bibr133-1534735418794885]^ stated in its recent guidelines on nutrition in cancer patients that "there are insufficient consistent clinical data to recommend glutamine to prevent radiation-induced enteritis/diarrhea, stomatitis, esophagitis, or skin toxicity." The MASCC/ISOO guideline has been updated from a recommendation against glutamine to "no guideline possible" for glutamine for oral or gastrointestinal mucositis.^[@bibr136-1534735418794885]^ The safety of glutamine has also been reviewed in view of emerging evidence that malignant cells can utilize glutamine as a mitochondrial substrate.^[@bibr137-1534735418794885]^ The glutamine doses investigated have ranged from 9 to 30 g daily in divided doses. As the lower dose has been shown to be beneficial in oral mucositis, it may be prudent to use the lower end of the dosage spectrum. Good oral hygiene is essential if honey-based interventions for mucositis are recommended. Activated charcoal may reduce symptoms associated with chemotherapy-induced mucositis including diarrhea. Clinical trials investigating the administration of probiotics to prevent treatment-induced intestinal toxicity has produced mixed results.^[@bibr124-1534735418794885]^ Studies have used various end-point parameters including stool frequency and stool consistency (described separately or as diarrhea grade 2-4), use of rescue anti-diarrheal medications, and microbiome shifts induced by chemotherapy or radiotherapy. The use of probiotics in the prevention or treatment of chemotherapy and/or radiotherapy-induced gastrointestinal toxicity appears to be beneficial and without significant side effects. The MASCC/ISOO guideline suggests that probiotics containing *Lactobacillus* species be used to prevent diarrhea in patients receiving chemotherapy and/or radiation therapy for a pelvic malignancy,^[@bibr136-1534735418794885]^ while the ESPEN guideline states that there are insufficient consistent clinical data to recommend probiotics to reduce radiation-induced diarrhea.

Conclusion {#section7-1534735418794885}
==========

There is plausible clinical evidence for the administration of honey, zinc, selenium, topical vitamin E, and glutamine as an adjuvant treatment to reduce the risk of developing oral mucositis during chemotherapy or radiotherapy. Activated charcoal, glutamine, and probiotics may also be beneficial in chemotherapy-induced diarrhea. Considering the excellent safety profile and resulting high therapeutic index, further research examining the mechanism of action and clinical efficacy of probiotics in chemotherapy- and radiotherapy-induced intestinal mucositis is warranted. Given that adverse disturbances in the oral and intestinal microbiomes can promote immune dysregulation and increase the risk of patient mortality, there is need for further research in this area.
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